GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (STU:TQ80) » Definitions » Cyclically Adjusted PB Ratio

Theratechnologies (STU:TQ80) Cyclically Adjusted PB Ratio : 3.45 (As of May. 25, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Theratechnologies Cyclically Adjusted PB Ratio?

As of today (2025-05-25), Theratechnologies's current share price is €2.28. Theratechnologies's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2025 was €0.66. Theratechnologies's Cyclically Adjusted PB Ratio for today is 3.45.

The historical rank and industry rank for Theratechnologies's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:TQ80' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.98   Med: 6.66   Max: 25.79
Current: 3.48

During the past years, Theratechnologies's highest Cyclically Adjusted PB Ratio was 25.79. The lowest was 0.98. And the median was 6.66.

STU:TQ80's Cyclically Adjusted PB Ratio is ranked worse than
72.01% of 668 companies
in the Biotechnology industry
Industry Median: 1.485 vs STU:TQ80: 3.48

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Theratechnologies's adjusted book value per share data for the three months ended in Feb. 2025 was €-0.511. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.66 for the trailing ten years ended in Feb. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Theratechnologies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Theratechnologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies Cyclically Adjusted PB Ratio Chart

Theratechnologies Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.74 9.89 7.60 1.75 1.58

Theratechnologies Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.70 1.49 1.56 1.58 2.29

Competitive Comparison of Theratechnologies's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Theratechnologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theratechnologies's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Theratechnologies's Cyclically Adjusted PB Ratio falls into.


;
;

Theratechnologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Theratechnologies's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.28/0.66
=3.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theratechnologies's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2025 is calculated as:

For example, Theratechnologies's adjusted Book Value per Share data for the three months ended in Feb. 2025 was:

Adj_Book=Book Value per Share/CPI of Feb. 2025 (Change)*Current CPI (Feb. 2025)
=-0.511/128.7859*128.7859
=-0.511

Current CPI (Feb. 2025) = 128.7859.

Theratechnologies Quarterly Data

Book Value per Share CPI Adj_Book
201505 0.397 100.263 0.510
201508 0.794 100.579 1.017
201511 0.851 100.421 1.091
201602 0.819 100.421 1.050
201605 1.013 101.765 1.282
201608 1.067 101.686 1.351
201611 1.125 101.607 1.426
201702 1.589 102.476 1.997
201705 1.639 103.108 2.047
201708 1.636 103.108 2.043
201711 1.521 103.740 1.888
201802 1.368 104.688 1.683
201805 1.342 105.399 1.640
201808 1.613 106.031 1.959
201811 1.603 105.478 1.957
201902 1.564 106.268 1.895
201905 1.457 107.927 1.739
201908 1.403 108.085 1.672
201911 1.168 107.769 1.396
202002 0.985 108.559 1.169
202005 0.735 107.532 0.880
202008 0.374 108.243 0.445
202011 0.142 108.796 0.168
202102 1.424 109.745 1.671
202105 1.219 111.404 1.409
202108 0.961 112.668 1.098
202111 0.654 113.932 0.739
202202 0.376 115.986 0.417
202205 -0.463 120.016 -0.497
202208 -0.749 120.569 -0.800
202211 -0.915 121.675 -0.968
202302 -1.247 122.070 -1.316
202305 -1.579 124.045 -1.639
202308 -1.580 125.389 -1.623
202311 -0.419 125.468 -0.430
202402 -0.496 125.468 -0.509
202405 -0.467 127.601 -0.471
202408 -0.388 127.838 -0.391
202411 -0.518 127.838 -0.522
202502 -0.511 128.786 -0.511

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Theratechnologies  (STU:TQ80) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Theratechnologies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Theratechnologies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies Business Description

Traded in Other Exchanges
Address
2015, rue Peel, 11th Floor, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

Theratechnologies Headlines

No Headlines